Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,460 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 1 / Phase 2 | 880 | BioNTech SEINDUSTRY | 10 | Aug 5, 2026 | clinicaltrials |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | active not recruiting | Phase 2 | 124 | Acerta Pharma BVINDUSTRY | 10 | Aug 4, 2026 |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05526755 | A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)(TARGET) | active not recruiting | Phase 2 | 188 | AstraZenecaINDUSTRY | 11 | Aug 3, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies(ELM-2) | active not recruiting | Phase 2 | 515 | Regeneron PharmaceuticalsINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT04554914 | A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | active not recruiting | Phase 2 | 190 | Pierre Fabre MedicamentINDUSTRY | 7 | Jul 31, 2026 | clinicaltrials |
| NCT04557098 | A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-1) | active not recruiting | Phase 2 | 194 | Janssen Research & Development, LLCINDUSTRY | 11 | Jul 31, 2026 | clinicaltrials |
| NCT04617925 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis(EMN27) | completed | Phase 2 | 35 | Stichting European Myeloma NetworkNETWORK | 6 | Jul 31, 2026 | clinicaltrials |
| NCT05217446 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer(SEAMARK) | active not recruiting | Phase 2 | 108 | PfizerINDUSTRY | 15 | Jul 31, 2026 | clinicaltrials |
| NCT05669989 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | enrolling by invitation | Phase 2 | 70 | SanofiINDUSTRY | 17 | Jul 31, 2026 | clinicaltrials |
| NCT06055959 | A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis(ziMyG) | recruiting | Phase 2 / Phase 3 | 8 | UCB Biopharma SRLINDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT06425302 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma(GOLSEEK-2) | active not recruiting | Phase 2 | 95 | CelgeneINDUSTRY | 13 | Jul 31, 2026 | clinicaltrials |
| NCT07227350 | L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) | recruiting | Phase 2 | 180 | Philogen S.p.A.INDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT03363373 | Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | active not recruiting | Phase 2 | 122 | Y-mAbs TherapeuticsINDUSTRY | 9 | Jul 30, 2026 | clinicaltrials |
| NCT06486883 | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype(PONTIAC) | recruiting | Phase 2 | 200 | MedSIROTHER | 10 | Jul 30, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 205 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT03075696 | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 940 | Hoffmann-La RocheINDUSTRY | 13 | Jul 29, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | enrolling by invitation | Phase 2 | 332 | Taiho Oncology, Inc.INDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT05645692 | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 204 | Hoffmann-La RocheINDUSTRY | 15 | Jul 28, 2026 | clinicaltrials |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 2 / Phase 3 | 860 | Daiichi SankyoINDUSTRY | 19 | Jul 28, 2026 | clinicaltrials |
| NCT01843374 | Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma(Tremelimumab) | active not recruiting | Phase 2 | 571 | MedImmune LLCINDUSTRY | 19 | Jul 27, 2026 | clinicaltrials |
| NCT05460000 | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy(N-Plus) | recruiting | Phase 2 | 640 | North Eastern German Society of Gynaecological OncologyOTHER | 6 | Jul 27, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
| NCT06282159 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)(MAGIC) | active not recruiting | Phase 2 | 65 | Dianthus TherapeuticsINDUSTRY | 14 | Jul 27, 2026 | clinicaltrials |
| NCT04939610 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors(LuMIERE) | recruiting | Phase 1 / Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 24, 2026 | clinicaltrials |
| NCT05253846 | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29(ShorTrip) | active not recruiting | Phase 2 | 63 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07228442 | L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma | recruiting | Phase 2 | 92 | Philogen S.p.A.INDUSTRY | 5 | Jul 24, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | terminated | Phase 1 / Phase 2 | 179 | GenmabINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05957367 | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 94 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT07172919 | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation | recruiting | Phase 2 | 14 | AmgenINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT02546986 | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 2 | 100 | CelgeneINDUSTRY | 6 | Jul 22, 2026 | clinicaltrials |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors(innovaTV 207) | active not recruiting | Phase 2 | 350 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | terminated | Phase 1 / Phase 2 | 214 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT04879329 | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | recruiting | Phase 2 | 372 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 12 | Jul 22, 2026 | clinicaltrials |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | active not recruiting | Phase 2 | 120 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT03445000 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer(ALERT-lung) | terminated | Phase 2 | 14 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jul 21, 2026 | clinicaltrials |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT07227870 | L19IL2/TNF in Patients With Basal Cell Carcinoma | recruiting | Phase 2 | 92 | Philogen S.p.A.INDUSTRY | 5 | Jul 21, 2026 | clinicaltrials |
| NCT07302451 | REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)(REDI-CaP) | recruiting | Phase 2 | 50 | National Cancer Institute, NaplesOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03455504 | Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia(V-FIRST) | completed | Phase 2 | 124 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | active not recruiting | Phase 2 | 155 | Daiichi SankyoINDUSTRY | 12 | Jul 20, 2026 | clinicaltrials |
| NCT05775289 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | completed | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 11 | Jul 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials